Original Article
Radiological differential diagnosis between fibrosis and recurrence after stereotactic body radiation therapy (SBRT) in early stage non-small cell lung cancer (NSCLC)
Translational Lung Cancer Research
2017;
6
(Suppl 1)
:S1-S7
.
(21 December 2017)
Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta- analysis
Translational Lung Cancer Research
2017;
6
(Suppl 1)
:S8-S20
.
(21 December 2017)
Review Article
Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors: the necessity of repeated molecular analysis
Translational Lung Cancer Research
2017;
6
(Suppl 1)
:S21-S34
.
(21 December 2017)
Editorial
Avelumab—a new programmed death-ligand 1 inhibitor against advanced non-small cell lung cancer
Translational Lung Cancer Research
2017;
6
(Suppl 1)
:S35-S38
.
(21 December 2017)
Epidermal growth factor tyrosine kinase inhibitor therapy inferior to second-line chemotherapy in EGFR wild-type non-small cell lung cancer patients: results of French nationwide observational study
Translational Lung Cancer Research
2017;
6
(Suppl 1)
:S39-S40
.
(21 December 2017)
Avelumab: another active immune checkpoint inhibitor in nonsmall cell lung cancer
Translational Lung Cancer Research
2017;
6
(Suppl 1)
:S41-S43
.
(21 December 2017)
Young low and middle-income country (LMIC) smokers— implications for global tobacco control
Translational Lung Cancer Research
2017;
6
(Suppl 1)
:S44-S46
.
(21 December 2017)
Perspectives in small cell lung cancer: is something moving?
Translational Lung Cancer Research
2017;
6
(Suppl 1)
:S47-S50
.
(21 December 2017)
Reproducibility of PD-L1 assessment in non-small cell lung cancer—know your limits but never stop trying to exceed them
Translational Lung Cancer Research
2017;
6
(Suppl 1)
:S51-S54
.
(21 December 2017)
The rapidly evolving treatment landscape for patients with brain metastases from epidermal growth factor receptor mutated nonsmall cell lung cancer
Translational Lung Cancer Research
2017;
6
(Suppl 1)
:S55-S57
.
(21 December 2017)
Raising the bar: the future of EGFR inhibition in non-small lung cancer
Translational Lung Cancer Research
2017;
6
(Suppl 1)
:S58-S61
.
(21 December 2017)
Osimertinib as first-line treatment of EGFR mutant advanced nonsmall- cell lung cancer
Translational Lung Cancer Research
2017;
6
(Suppl 1)
:S62-S66
.
(21 December 2017)
Small-cell lung cancer in the era of immunotherapy
Translational Lung Cancer Research
2017;
6
(Suppl 1)
:S67-S70
.
(21 December 2017)
Can we omit radiotherapy in case of brain metastases for patients with mutant EGFR lung adenocarcinoma?
Translational Lung Cancer Research
2017;
6
(Suppl 1)
:S71-S73
.
(21 December 2017)
The reproducibility of PD-L1 scoring in lung cancer: can the pathologists do better?
Translational Lung Cancer Research
2017;
6
(Suppl 1)
:S74-S77
.
(21 December 2017)
Pembrolizumab in advanced pretreated small cell lung cancer patients with PD-L1 expression: data from the KEYNOTE-028 trial: a reason for hope?
Translational Lung Cancer Research
2017;
6
(Suppl 1)
:S78-S83
.
(21 December 2017)
KEYNOTE-028: how do we use immunotherapy in small cell lung cancer?
Translational Lung Cancer Research
2017;
6
(Suppl 1)
:S84-S87
.
(21 December 2017)
Treating epidermal growth factor receptor-mutated non-small cell lung cancer—is dacomitinib the winner?
Translational Lung Cancer Research
2017;
6
(Suppl 1)
:S88-S91
.
(21 December 2017)
Meet the Professor
Dr. Tetsuya Mitsudomi: next generation sequencing may become the focus of the future study in the field of lung cancer
Translational Lung Cancer Research
2017;
6
(Suppl 1)
:S92-S93
.
(21 December 2017)
Dr. Peter Ujhazy: research for the greater good
Translational Lung Cancer Research
2017;
6
(Suppl 1)
:S94-S96
.
(21 December 2017)
Dr. Mari Mino-Kenudson: challenges and future developments in the field of biopsy
Translational Lung Cancer Research
2017;
6
(Suppl 1)
:S97-S98
.
(21 December 2017)
Dr. Viola Zhu: is ethnicity a prognostic factor in lung cancer?
Translational Lung Cancer Research
2017;
6
(Suppl 1)
:S99-S100
.
(21 December 2017)
Dr. Erik Thunnissen: how to appropriately optimize the handling of surgically resected specimens
Translational Lung Cancer Research
2017;
6
(Suppl 1)
:S101-S102
.
(21 December 2017)
Professor Jacek Jassem: we can never emphasize too much on tobacco-control
Translational Lung Cancer Research
2017;
6
(Suppl 1)
:S103-S105
.
(21 December 2017)
Presidential remarks: WCLC 2017, a successful conference with record-breaking attendance and high scientific quality
Translational Lung Cancer Research
2017;
6
(Suppl 1)
:S106-S107
.
(21 December 2017)
Professor Heather A. Wakelee: facing new progress in lung cancer research, keep in mind how do we best help patients
Translational Lung Cancer Research
2017;
6
(Suppl 1)
:S108-S110
.
(21 December 2017)
Dr. Giannis Mountzios: immunotherapy, an “earthquake” in the treatment of advanced lung cancer
Translational Lung Cancer Research
2017;
6
(Suppl 1)
:S111-S112
.
(21 December 2017)
Prof. Silvia Novello: our job—a choice of life that has to be renewed every day
Translational Lung Cancer Research
2017;
6
(Suppl 1)
:S113-S115
.
(21 December 2017)
Disclosure:
The supplement was published without any sponsorship or funding.